Olympus opts for Munich site for life sciences R&D (research and development) centre:
This article was originally published in Clinica
Executive Summary
Japanese camera and medical products developer Olympus has opted to locate its new life science research and development centre in Munich, Germany. Tokyo-based Olympus will invest some Euro15m ($21m) in the project, which will be opened officially in October. By 2009, it will be employing a staff of 450, who will be involved in production as well as R&D in the fields of molecular diagnostics, laboratory automation and digital processing in microscopy. Olympus' regional HQ, Olympus Europa Holding, is located in Hamburg. The proximity of the University Hospital Grosshadern to the new Bavarian site was an advantage, said Olympus regional executive managing director Dr Helmut Kohler. The group will be working in close co-operation with the hospital.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.